Seagen announces jury award in patent infringement case against daiichi sankyo

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced that a jury in the u.s. district court for the eastern district of texas found that daiichi sankyo co. ltd. (“daiichi sankyo”) infringed seagen's u.s. patent no. 10,808,039 by selling in the united states its enhertu® product (trastuzumab deruxtecan; ds-8201). seagen was awarded damages of $41.82 million for past infringement of the patent. in addition, seagen will request additional royalty payments for future sales of
SGEN Ratings Summary
SGEN Quant Ranking